![A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs](/i/c/59688bbc-1963-adc7-546d-013340e896a8.webp)
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this
2023-11-22 19:50
![Eisai Alzheimer Drug Shows Promise in Injected-At-Home Form](/i/c/f9af64f3-4c3e-ec40-7425-aa877e697281.webp)
Eisai Alzheimer Drug Shows Promise in Injected-At-Home Form
An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes exceeded the power
2023-10-26 08:19
![Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal](/i/c/e4ab9707-13a4-2295-87b8-e21843f13774.webp)
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech
2023-10-23 13:50
![Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US](/i/c/bfaa0415-61ea-ea09-56de-a416b7d8c546.webp)
Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US
Eisai Co.’s breakthrough Alzheimer’s disease drug won clearance from Japanese regulators after the medicine was fully cleared in
2023-09-25 14:24
![Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US](/i/c/26309d98-4c2b-6630-c3a2-e92070b77028.webp)
Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US
Eisai Co.’s breakthrough Alzheimer’s disease drug is poised to gain the backing of Japanese regulators after the medicine
2023-08-21 21:25
![Sanofi Was Mystery Bidder That Lost Reata to Biogen](/i/c/8dc9e120-da96-0852-ea71-17dfe1eeb228.webp)
Sanofi Was Mystery Bidder That Lost Reata to Biogen
Biogen Inc. narrowly beat out Sanofi SA to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, according to
2023-08-16 03:54
![Sage Tumbles as Depression Pill Approval Omits Major Disorder](/i/c/566a73df-b9f2-38e4-226c-5dc68f617eb5.webp)
Sage Tumbles as Depression Pill Approval Omits Major Disorder
Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum
2023-08-07 20:29
![Women Hold a Third of S&P 500 Boards Seats With Gains in June](/i/c/d4303595-e2ce-8a43-d1e9-5568866cdf54.webp)
Women Hold a Third of S&P 500 Boards Seats With Gains in June
Women retained control of a record high one-third of S&P 500 board seats in June as companies moved
2023-07-28 21:46
![Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion](/i/c/c0333e56-36a1-9601-9568-62fac445ccc9.webp)
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion
Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion including debt to expand its rare disease
2023-07-28 19:49
![Medicare Proposes Expanding Patient Access to Alzheimer’s Scans](/i/c/c6cbeab9-c47e-db61-7ab9-036e842008ff.webp)
Medicare Proposes Expanding Patient Access to Alzheimer’s Scans
The US Medicare program will roll back rules that limited coverage for an expensive imaging scan for people
2023-07-18 06:26
![Lilly Applies for Alzheimer’s Drug’s US Approval After Trial Success](/i/c/8af79b5e-72ef-4fc9-41b3-a8f93180bb24.webp)
Lilly Applies for Alzheimer’s Drug’s US Approval After Trial Success
Eli Lilly & Co. said it applied for full US approval of its Alzheimer’s disease drug that’s expected
2023-07-17 22:45
![Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program](/i/c/b89b1958-8e9f-41e5-34b7-296018d1a252.webp)
Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
2023-07-11 09:46